Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) have now 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 1064 and 680 suggesting an average Analsyt target price of $912.52. Given that the stocks previous close was at $804.28 this would imply there is now a potential upside of 13.5%. There is a 50 day moving average of $826.05 and the 200 moving average now moves to $776.49. The market capitalization for the company is 86.53B. The stock price for the company is currently 797.04 USD
The potential market cap would be $98,170,512,123 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 21.05, revenue per share of 118.47 and a 9.55% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
